TTNP - TITAN PHARMACEUTICALS INC
IEX Last Trade
3.46
-0.180 -5.202%
Share volume: 0
Last Updated: Fri 27 Dec 2024 07:32:15 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$3.64
-0.18
-4.95%
Fundamental analysis
43%
Profitability
50%
Dept financing
20%
Liquidity
75%
Performance
34%
Performance
5 Days
11.42%
1 Month
-6.48%
3 Months
-34.12%
6 Months
-34.95%
1 Year
-44.65%
2 Year
-77.15%
Key data
Stock price
$3.46
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.48 - $14.80
52 WEEK CHANGE
-$56.24
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: David E. Lazar
Region: US
Website: titanpharm.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: titanpharm.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company was incorporated in 1992 and is based in South San Francisco, California.
Recent news